Beauty's Big Roll-Ups Are Running Out of Road. That's Good News for Founders in the Lower Mid-Market.

Global beauty M&A looks like a party that never ended. BeautyMatter's Deal Index tracked 83 transactions in the first quarter of 2026 alone, up more than 40% year-on-year, and one single beauty portfolio changed hands for as much as $40 billion. Unilever paid a reported $1.5 billion for a men's grooming brand. L'Oréal is stitching together Kering's luxury fragrance house Creed alongside licensing rights for Gucci and Balenciaga perfume lines.

Look past the headline multiples, though, and a more interesting story is playing out. It's one that matters far more to founder-owned businesses in Australia, New Zealand and Southeast Asia than another mega-deal in Paris or New York.

The thesis behind the last generation of beauty roll-ups is aging badly.

Investors and bankers surveyed by Beauty Independent for their 2026 M&A forecast put it bluntly: private equity firms holding color-cosmetics-heavy platforms built four-plus years ago are "approaching decision points," and the thesis behind many of them "is starting to look pretty threadbare." Their prediction is stark: expect at least one of these roll-ups to either bolt on assets in search of "new news" or accept a disappointing exit in 2026.

Meanwhile the BeautyMatter data shows exactly where capital is rotating instead. Brand portfolio deals were up 100% year-on-year in the first three quarters of 2025. Retail-channel deals rose 41.7%. Men's and grooming climbed 33.3%. But personal care fell 68%, fragrance fell 57%, haircare fell 33%, and, notably, general health and wellness deal activity fell 11%, even as "the wellness multiplier" (GLP-1s, aesthetic procedures, health prioritization) remains one of the sector's most cited long-term themes.

That's not a contradiction. It's dispersion. Capstone Partners' latest update is explicit about what's actually winning: targets with genuine vertical integration, clinically-proven efficacy, dermatologist-backed credibility, and the ability to operate across category boundaries: beauty blurring into wellness, wellness blurring into health. Generic, undifferentiated brands are struggling to move at any price.

Why this matters more in the lower mid-market than at the top of the stack

The mega-deals get the headlines because the numbers are large and the buyers are famous. But the roll-up hangover described above was built on a very specific pattern: platforms assembled quickly during a low-rate, high-multiple window, stitched together on the assumption that scale alone would create value, without the underlying operational discipline to back it up. When the discipline wasn't there, growth stalled and the thesis calcified.

That pattern is largely a function of how those platforms were built at scale and speed. It is far less common, and far more fixable, in founder-owned, lower mid-market businesses, where the operator is still in the building, the customer relationship is still direct, and the brand hasn't yet been abstracted into a portfolio line item.

This is precisely the segment we spend our time in. Lower mid-market, privately owned healthcare, wellness and beauty, consumer, and specialty retail businesses across Australia, New Zealand and Southeast Asia rarely show up in the global deal trackers. But the same forces reshaping the top of the market, including demand for genuine differentiation, category-crossing relevance, clinical or evidence-backed credibility, and disciplined rather than debt-fuelled scale, apply just as much to a Brisbane skincare clinic group or an Auckland specialty retailer as they do to a $40 billion global portfolio.

Australia's own PE market data supports this. IMARC Group's research shows buyout activity remains the dominant structure locally, and family-owned businesses at succession inflection points continue to generate roughly 40–50% of Australian mid-market buyout deal flow, a very different dynamic to the "assemble fast, sort it out later" roll-ups now unwinding overseas.

The founder takeaway

One line from Beauty Independent's 2026 forecast deserves to be pinned above every founder's desk right now: capital remains available, but real financial results matter more than fundraising momentum. That is exactly the opposite of the environment that produced the last cycle's threadbare roll-ups. It is exactly the environment in which a well-run, differentiated, evidence-backed business in a fragmented lower mid-market category can command a premium rather than get lost in a portfolio.

If you are building a healthcare, wellness, beauty, consumer or specialty retail business in this region and wondering whether the global M&A slowdown in your category applies to you, it largely doesn't. The capital chasing scale-for-scale's-sake is pulling back. The capital chasing genuine, well-run, category-relevant businesses with a real growth story is just getting more selective about where it lands. That is a better market for founders with something real to sell than the one that came before it.

By Astra Capital

If any of this resonates

We spend our time talking with founders and operators across these exact categories about where their business sits in this cycle, whether that's actively exploring a transaction or simply thinking a few years ahead. If you're building something in healthcare, wellness and beauty, consumer, or specialty retail in Australia, New Zealand or Southeast Asia and want an outside perspective on where you sit in this market, we'd welcome the conversation. Reach out to the Astra Capital team.

Sources

• Capstone Partners, Beauty M&A Update (December 2025)
• Beauty Independent, Beauty's 2026 M&A Forecast: Measured Acceleration, Bifurcation and Selectivity (January 2026)
• BeautyMatter, Will 2026 Be the Year of the Private Equity Comeback? and Beauty Deals: Investment + M&A Transactions Q1 2026 (January 2026)
• Forbes, Why Beauty Is The Hottest Bet In Consumer M&A (May 2026)
• DC Advisory, DC Discusses: Global M&A Shaping the Future of Beauty
• Griffin Financial Group, Beauty and Personal Care M&A – Q1 2026
• IMARC Group, Australia Private Equity Market Size & Forecast 2026–2034

This article is provided for general informational purposes only and does not constitute financial, investment, legal or tax advice, nor an offer, solicitation or recommendation in respect of any security, fund or transaction. Views expressed are those of Astra Capital Proprietary Limited ACN 691553849 at the time of publication and may change without notice. Information sourced from third parties is believed to be reliable but has not been independently verified and no warranty is given as to its accuracy or completeness. Past performance and industry trends are not indicative of future results. Readers should seek independent professional advice before making any investment decision. © Astra Capital Proprietary Limited ACN 691553849. All rights reserved.